Search Results
Your search for ,sAy matches 1419 pages
Showing 401 - 450Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer
Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...
The Piano
The ASCO Post is pleased to reproduce installments of the Art of Oncology, as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
A Doctor Battles a Deadly Disease and Turns Hope Into Action
From his early days, David Fajgenbaum, MD, was an overachiever in academics and sports, funneling his relentless drive and laser-like focus into everything he did. He dreamed of becoming a quarterback at a division I school, which he achieved, garnering a full scholarship to Georgetown University,...
Expert Point of View: Ryan J. Sullivan, MD
The study’s invited discussant, Ryan J. Sullivan, MD, Assistant Professor of Medicine, Harvard Medical School, and Assistant Professor in Hematology/Oncology at Massachusetts General Hospital, welcomed the positive results from the updated analysis of lifileucel in treatment-refractory melanoma....
A Long-Time Student of Leadership, Brian J. Bolwell, MD, FACP, Ultimately Takes the Reins at the Taussig Cancer Institute
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, interviewed his colleague Brian J. Bolwell, MD, FACP, Chairman of the Cleveland Clinic Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic. Among other things, Dr. Bolwell discussed his...
Addressing Discrimination and Bias in Medical Education
“As a medical student, I often felt marginalized from my medical community. I have been told that my name is ‘not American,’ fallen prey to being confused for support staff such as a janitor (even while wearing my white coat), and been asked questions like, ‘Where are you really from?’ or ‘How old...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
AMA Board of Trustees Pledges Action Against Racism and Police Brutality
At a virtual Special Meeting of the American Medical Association (AMA) House of Delegates, the AMA Board of Trustees pledged action to confront systemic racism and police brutality. The AMA released the following statement that was approved at its meeting on June 5, 2020: The AMA recognizes that...
Extended-Fraction Radiation Therapy for Bone Metastases Represents Low-Value Care but Continues to Be Widely Practiced
An analysis of radiation therapy patterns among more than 12,000 Medicare patients treated for bone metastases found that 23.4% received extended-fraction radiation therapy, “wasting both health-care dollars and precious patient time,” according to the investigators.1 One-third of the treating...
Determining the Best Place to Die for Patients With Cancer
Studies have shown a disconnect between where patients say they want to die and where they actually die. According to research from Stanford School of Medicine, although an overwhelming majority of Americans—about 80%—would prefer to die at home, just 20% do. In fact, 60% die in acute care...
Immunogenomic Characteristics of Advanced Clear Cell Kidney Cancer Treated With Checkpoint Inhibitors
By analyzing tumors from patients treated with immunotherapy for advanced kidney cancer in three clinical trials, scientists have identified several features of the tumors that influence their response to immune checkpoint inhibitors. The research was presented during the ASCO20 Virtual Scientific...
The Power of mCODE
ASCO Chief Executive Officer Clifford A. Hudis, MD, FACP, FASCO, hosts the ASCO in Action Podcast, which focuses on policy and practice issues affecting providers and patients. An excerpt of a recent episode is shared below; it has been edited for length and clarity. Listen to the full podcast on...
When Is It Time to Pass?
Assisted suicide gets a lot of press, as if it were a new event. About 20 to 30 years ago, it was ever present but neither defined nor acknowledged. When patients left the hospital for what they and I believed to be the last time, I did one or both of two things: gave them my home number or, if...
My Future Is Doled Out in Increments of 6 Months
In the fall of 2015, I was looking forward to a trip to Florida for a visit with my daughter and her family, along with a little relaxation. The evening before the trip, I experienced some abdominal pain that my wife, Angela, and I thought might be appendicitis. Concerned the problem could...
Expert Point of View: Scott T. Tagawa, MD, MS
Discussant Scott T. Tagawa, MD, MS, of Weill Cornell Medicine, New York, congratulated Dr. Hofman and coauthors on this first randomized trial any PSMA-targeted therapy, and was cautiously optimistic about the targeted radioligand treatment being adopted as post-docetaxel therapy in men with...
A Nobel Laureate’s Road to Research Is Not Without Challenges
The 2019 Nobel Prize for Physiology and Medicine was jointly awarded to three researchers. Their discoveries paved the way for promising new strategies to treat anemia, cancer, and many other diseases. One of the three Nobel Laureates is William G. Kaelin, Jr, MD, who continues his research at his...
International Medical and Radiation Oncologist Balances Cancer Research and Clinical Practice
The Revolutions of 1989 that resulted in the end of communist rule in Central and Eastern Europe and beyond began in Poland. Perhaps if not for that social upheaval, the career of internationally renowned oncologist Jacek Jassem, MD, PhD, would have taken a very different path. Dr. Jassem had fled...
Expert in Clinical Trial Methodology Makes His Mark in Genitourinary Cancer
In 2019, at the ASCO Annual Meeting, Ian Tannock, MD, PhD, DSc, FASCO, was honored with the Allen S. Lichter Visionary Award for his contributions to the fields of genitourinary and breast cancers as well as his efforts to optimize clinical trial design. The title of his lecture was “Clinical...
Expert Point of View: Axel Grothey, MD
Sharing his perspective on KEYNOTE-177 with The ASCO Post was Axel Grothey, MD, Director of GI Cancer Research at the West Cancer Center, OneOncology, Memphis. “This is a very important, highly anticipated study,” he said. “It’s the first randomized trial of any checkpoint inhibitor in...
New Article Analyzes Impact of PBMs on Quality Cancer Care
Recently, an article and accompanying infographic published in JCO Oncology Practice examined the impact pharmacy benefit managers (PBMs) have on cancer care delivery. The article is part of ASCO’s State of Cancer Care in America series, which explores challenges and opportunities in today’s...
The Arc of Therapy—From Cure to Humbling Legacy
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
What Have I Learned in More Than Half a Century in Cancer Medicine?
My journey in cancer medicine started in June 1968, when I traveled from Lebanon to New York to begin my fellowship in medical oncology at Memorial Sloan Kettering Cancer Center. Since then, and on a daily basis, I have been actively engaged in the treatment of patients with cancer and in cancer...
Gynecologic Oncologist Describes His New Normal in a New York Hospital
During the COVID-19 pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Alexander Melamed, MD, MPH, a gynecologic oncologist and Assistant Professor of Obstetrics & Gynecology at NewYork-Presbyterian/Columbia...
Being Interviewed on Zoom? Here Are Some Professional Tips
You’ve agreed to be interviewed on Zoom. If you’re like most people, the technology itself isn’t a barrier. (And if it is, you can consult our step-by-step guide to using Zoom at https://bit.ly/2yxcTN0.) However, you might be less sure about what you can do to make the best impression (and the most ...
United Against Cancer to Accelerate Progress for Patients
When I chose my Presidential theme for the 2020 ASCO Annual Meeting, “Unite and Conquer: Accelerating Progress Together,” in early 2019, I never imagined it would take on a new meaning 12 months later. The world is grappling with the COVID-19 pandemic, and, even as we practice social distancing, I...
Online Guide Offers Tips for Communicating With Patients During the COVID-19 Pandemic
A NEW ONLINE GUIDE provides tips to help oncology and other clinicians navigate the difficult and distressing communications with patients that have arisen during the COVID-19 pandemic. Anthony Back, MD, a medical oncologist and palliative medicine specialist at the University of Washington and...
Study Finds a High Rate of Intra- and Postoperative Conversions to Total Thyroidectomy
The overall risk of needing a total thyroidectomy was found to be 19.4% for patients undergoing lobectomy for indeterminate and high-risk thyroid nodule, according to a report published by Moore et al in the World Journal of Surgery. The study also found that 21% and 26.5% of patients originally...
Quitting Smoking at Any Point Improves Lung Cancer Survival, Study Finds
People who quit smoking at any time—even 2 years before a lung cancer diagnosis—improve their chances of survival after being diagnosed with the disease, according to the results of a large international study presented by Fares et al in a press briefing in advance of the ASCO20 Virtual Scientific...
In ‘Remembering Mum,’ Siblings Honor Their Mother With Action and Innovation
It’s one of the worst things Claire Paxman can recall: She’s 14 years old, using orange-handled kitchen scissors to cut her mother’s hair. “You shouldn’t be standing in the bathroom cutting your mom’s hair because of chemotherapy,” said Claire as she describes that defining childhood moment when ...
My ASCO Journey: Opportunities for Gratitude and Breaking Glass Ceilings
In my native language, there is a saying that is translated as, “A child who does not travel only appreciates their mother’s cooking.” In the broad sense, as we grow up and experience the different things that life has to offer, two things happen if we allow our minds to open up: we realize there...
I Have Multiple Myeloma and Am Concerned About the Coronavirus
In hindsight, the symptoms I began experiencing in the fall of 2013—sudden excruciating back bone pain and severe fatigue—should have tipped me off that I had a serious disease, but 7 years ago, they were easy to explain away. The bone pain was similar to what I had experienced several years...
Grace and Forgiveness
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Pooled Analysis Supports Benefit of Dual HER2-Targeted Therapy, but Questions Remain
In the treatment of HER2-positive early breast cancer, patients who receive dual HER2-targeted therapy in both the neoadjuvant and adjuvant settings are less likely to experience recurrence than those who received dual therapy only as neoadjuvant treatment, according to a pooled analysis of...
Distinct New MDS Subtype Proposed Based on Presence of Genetic Mutation
In a special report published by Malcovati et al in the journal Blood, an international working group of experts in myelodysplastic syndromes (MDS) has proposed the recognition of a distinct subtype of MDS based on the presence of a nonheritable genetic mutation that causes the disease. The...
Expert Point of View: Alexandra Leary, MD, PhD
Alexandra Leary, MD, PhD, of the Gustave Roussy Institute of Oncology, Paris, underscored the controversy surrounding the use of neoadjuvant chemotherapy in advanced ovarian cancer, suggesting the discord may be “more cultural and emotional than scientific” to some degree. “Some countries, such as ...
Treating Colorectal Cancer in the Time of COVID-19
The treatment of colorectal cancer has always been something of an art—but never more so than during the COVID-19 pandemic. The ASCO Post asked three experts in this malignancy to share their concerns and their approaches to achieving good patient outcomes while minimizing the risk of COVID-19...
Negotiating the Obstacles to Conducting Clinical Trials of Immunotherapy During the Coronavirus Pandemic
Coronavirus disease 2019 (COVID-19) is perhaps the biggest challenge health-care systems have ever had to face. As part of a series of interviews The ASCO Post is conducting with oncologists, we talked with Charles G. Drake, MD, PhD, about the impact of COVID-19 on his practice and on the conduct...
Adapting Adjuvant Endocrine Therapy by Patient Age and Risk
The individualization and optimization of adjuvant endocrine therapy for breast cancer are important and not always simple. Guidance on this issue was offered at the 2020 Miami Breast Cancer Conference by Joyce O’Shaughnessy, MD, the Celebrating Woman Chair in Breast Cancer Research at Baylor...
Chemotherapy and the Sweat Lodge
The ASCO Post is pleased to reproduce installments of Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays, historical...
Survey Shows COVID-19 Pandemic Is Affecting Patients’ Access to Cancer Care
Patients with cancer and those who have recently completed treatment are finding it challenging to get necessary health care in the midst of the COVID-19 pandemic, and many are experiencing financial stress trying to afford care in an increasingly difficult economic environment. Delays in Care...
A Hallmark Moment
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Using Respectful Language to Reduce Unconscious Bias in Oncology Care
An abstract presented at the 2019 ASCO Annual Meeting titled “Evaluating Unconscious Bias During Speaker Introductions at an International Oncology Conference,” by Narjust Duma, MD, Assistant Professor of Medicine and Thoracic Oncologist at the University of Wisconsin Carbone Cancer Center in...
Apixaban for Cancer-Associated Venous Thromboembolism
For patients with cancer, the oral blood thinner apixaban is at least as effective as dalteparin, a low–molecular-weight heparin given by injection, in preventing a repeat venous thromboembolism (VTE), with no excess in major bleeding events. These findings from the phase III Caravaggio study were...
Oncologists on the Front Lines of the COVID-19 Pandemic: A Conversation With Miriam A. Knoll, MD
During the coronavirus disease 2019 (COVID-19) pandemic, The ASCO Post will be interviewing oncologists on how they and their centers are dealing with the crisis. Here, we speak with Miriam A. Knoll, MD, a radiation oncologist at the John Theurer Cancer Center, Hackensack University Medical Center, ...
AML Pioneer and Giant, Clara D. Bloomfield, MD, FASCO, Dies at 77
Physicians and scientists interested in acute myeloid leukemia (AML) have lost one of the community’s shining lights with the death of Clara D. Bloomfield, MD, FASCO, on March 1, 2020, at age 77 years. Dr. Bloomfield is well known for her more than 50 years of groundbreaking research in blood...
Expert Point of View: Richard L. Schilsky, MD, FACP, FSCT, FASCO
Richard L. Schilsky, MD, FACP, FSCT, FASCO, Chief Medical Officer and Executive Vice President of ASCO, called the 74% response rate to cisplatin/gemcitabine “remarkable.” “What’s impressive to me is the high response rate, as well as the progression-free and overall survival data—these data are...
Trends in Deaths From Cutaneous Melanoma in the United States
Recent treatment advances in metastatic melanoma resulted in reductions in population-level mortality from the disease, according to a study published by Polsky et al in the American Journal of Public Health. Methods Researchers analyzed new cases and deaths from melanoma from nine U.S....
Continuous Coverage of COVID-19
The staff of The ASCO Post recognizes the steady flow of news on the novel coronavirus, or COVID-19. Here, we've compiled a list of links to articles and resources on the COVID-19 pandemic. If you have a report you'd like to share, please e-mail it to us at editor@ascopost.com. Direct From ASCO:...
Former ASCO President Sandra M. Swain, MD, FACP, FASCO, Shares Highlights of a Noted Career
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Sandra M. Swain, MD, FACP, FASCO, Professor of Medicine and Associate Dean for Research Development at Georgetown University Medical Center, and Vice President of MedStar Genetic Medicine at Medstar...
Treating Patients With Chronic Lymphocytic Leukemia in 2020
With the availability of a number of effective targeted agents for the treatment of chronic lymphocytic leukemia (CLL), the question arises whether chemotherapy still has a role in treating this malignancy. At the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, CLL...
